U.S., Dec. 18 -- ClinicalTrials.gov registry received information related to the study (NCT07288177) titled 'Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer' on Dec. 15.
Brief Summary: This Phase 2 study will be conducted in different countries around the world with up to about 240 participants.
The purpose of this study is to evaluate how well Rina-S works against lung cancer.
The treatment in this study is Rina-S monotherapy (by itself). All participants will receive active drug; no one will be given placebo.
The treatment duration will be different for every participant, but an average of 12 months is expected. Participants will be asked to attend 1 to 5 visits at the study clinic for...